Kuehne+Nagel supports Sanofi in multiple countries worldwide, including Hungary, the UK, and the UAE, by providing customised ...

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

Net sales down 10.0% to €911.9 million, driven by lower volumes for Sanofi and the suspension of production at Brindisi, only ...

Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s MHLW for use in conjunction with VRd to treat newly diagnosed ...

Major pharmaceutical products and medicines have jumped in prices despite and executive order by President Bola Tinubu, ...

Paris: Sanofi has announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in ...

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.

Sanofi's Sarclisa (isatuximab ... recently gained approval from China’s National Medical Products Administration, in particular for the Sarclisa-VRd combo for treating NDMM individuals who ...

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

DelveInsight's Advanced Therapy Medicinal Products Market Insights report provides the current and forecast market analysis, ...

An FDA vaccine advisory committee meeting to discuss next season’s flu vaccine has been canceled, potentially delaying the ...

Despite Sanofi-Synthélabo’s size, the company found itself forced to partner with larger pharmaceutical companies in order to continue successfully introducing new products in major markets ...